Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CTLA-4
Biotech
BioNTech sets survival standard in hard-to-treat cancer
BioNTech linked gotistobart to a median OS of 18.5 months, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
Nick Paul Taylor
Sep 14, 2026 4:15am
Solstice rises with $225M series A for next-gen CTLA-4 therapy
Sep 9, 2026 7:00am
Fierce Pharma
Merck's Welireg surprisingly fails in first-line kidney cancer
Apr 21, 2026 10:00am
BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial
Dec 8, 2025 7:47am
UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data
Nov 6, 2025 10:00am
Instil refills pipeline in $2B biobucks deal with ImmuneOnco
Aug 1, 2024 10:19am
